drugset / Trial / NCT04993586
Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose)
Phase 1/2
Completed
422 enrolled
AnGes, Inc.
Japan Agency for Medical Research and Development · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
This study will assess the safety and immunogenicity of AG0302-COVID19 in healthy volunteers.
Timeline
- Start
- 2021-07-29
- Primary completion
- 2021-12-10
- Completion
- 2022-09-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AG0302-COVID19 | Vaccine | 1 mg | Intramuscular |
| Subject | AG0302-COVID19 | Vaccine | 2 mg | Intramuscular |
| Subject | AG0302-COVID19 | Vaccine | 4 mg | Intramuscular |
| Subject | AG0302-COVID19 | Vaccine | 8 mg | Intramuscular |